- Conditions
- Coronary Artery Disease
- Interventions
- High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
- Drug · Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 2,476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 148
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Immunosuppression
- Interventions
- Tacrolimus, combination therapy
- Drug
- Lead sponsor
- Newark Beth Israel Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 2
- States / cities
- Newark, New Jersey • New York, New York
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
- Interventions
- lerodalcibep, Placebo
- Drug · Other
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio
- Conditions
- Acute Coronary Artery Syndrome
- Interventions
- intensive LDL-lowering therapy, standard statin monotherapy
- Device · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 31 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
- Conditions
- Medication Adherence
- Interventions
- systems-based and pharmacist-mediated program
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Lower Back Pain, Lumbosacral Radiculopathy
- Interventions
- Qutenza® 8% Capsaicin Topical System
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Summerville, South Carolina
- Conditions
- Hypercholesterolemia
- Interventions
- colesevelam HCl, placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • St Louis, Missouri • New Hyde Park, New York + 5 more
- Conditions
- Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
- Interventions
- sorafenib tosylate, valproic acid, sildenafil citrate
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes, Carotid Atherosclerosis
- Interventions
- FDA approved drugs to treat blood pressure and cholesterol
- Drug
- Lead sponsor
- Cynthia West
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 548 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2007
- U.S. locations
- 4
- States / cities
- Chinle, Arizona • Phoenix, Arizona • Lawton, Oklahoma + 1 more
- Conditions
- Glaucoma
- Interventions
- 0.005% Latanoprost dosed once.
- Drug
- Lead sponsor
- Nanduri, Padma, M.D., FACS
- Individual
- Eligibility
- 21 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Visalia, California
- Conditions
- Healthy
- Interventions
- atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
- Drug
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Familial Hypercholesterolemia - Heterozygous
- Interventions
- lerodalcibep 300 mg Monthly SC
- Biological
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
- Drug · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
- Conditions
- Human Immunodeficiency Virus I Infection
- Interventions
- Mycophenolate Mofetil 500Mg Tab
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Peripheral Arterial Disease
- Interventions
- Supervised Exercise, Vascular Assessment
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
- Interventions
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
- Drug · Other
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 32
- States / cities
- Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more
- Conditions
- Hypercholesterolemia
- Interventions
- Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more
- Conditions
- Type1diabetes
- Interventions
- BKR-017
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Coronary Artery Disease
- Interventions
- Rosuvastatin
- Drug
- Lead sponsor
- General University Hospital, Prague
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Maywood, Illinois • Iowa City, Iowa
- Conditions
- Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Cardiovascular Diseases, Pharmacists, Placebo Effect
- Interventions
- Virtual Statin Management (VSM)
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 898 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hypertension
- Interventions
- clevidipine, nicardipine
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 739 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 9
- States / cities
- Mobile, Alabama • Wichita, Kansas • New Orleans, Louisiana + 4 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost SR, LUMIGAN
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more
- Conditions
- Renal Transplantation
- Interventions
- Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more
- Conditions
- Hypercholesterolaemia
- Interventions
- Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 29
- States / cities
- Encino, California • Fresno, California • Oakland, California + 25 more